296. 胆道閉鎖症
[臨床試験数:53,薬物数:56(DrugBank:31),標的遺伝子数:43,標的パスウェイ数:50

Searched query = "Biliary atresia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003807-37-NL
(EUCTR)
01/12/202028/04/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Netherlands;Germany;New Zealand;China;Korea, Republic of
2EUCTR2019-003807-37-IT
(EUCTR)
10/09/202021/10/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) - BOLD Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
ALBIREO ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Germany;Netherlands;New Zealand;China;Korea, Republic of
3EUCTR2019-003807-37-FR
(EUCTR)
08/09/202027/04/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Germany;Netherlands;New Zealand;China;Korea, Republic of
4EUCTR2019-003807-37-GB
(EUCTR)
11/08/202017/04/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) - Biliary Atresia Odevixibat Liver Disease (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3New Zealand;United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of
5EUCTR2019-003807-37-HU
(EUCTR)
29/07/202017/04/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Germany;Netherlands;New Zealand;China;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04336722
(ClinicalTrials.gov)
July 10, 202027/3/2020Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai HepatoportoenterostomyBiliary AtresiaDrug: Odevixibat;Drug: PlaceboAlbireoNULLRecruitingN/A111 DaysAll200Phase 3United States;Belgium;Canada;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Spain
7EUCTR2019-003807-37-PL
(EUCTR)
05/05/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLNAFemale: yes
Male: yes
200Phase 3United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Netherlands;Germany;New Zealand;China;Korea, Republic of
8EUCTR2019-003807-37-DE
(EUCTR)
15/05/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLNAFemale: yes
Male: yes
200Phase 3Canada;Poland;Belgium;Malaysia;Australia;Denmark;Germany;Netherlands;United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;New Zealand;China;Korea, Republic of
9EUCTR2019-003807-37-BE
(EUCTR)
18/06/2020This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD) Biliary Atresia
MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Product Name: Odevixibat
Product Code: A4250
INN or Proposed INN: Odevixibat
Albireo ABNULLNAFemale: yes
Male: yes
200Phase 3United States;Taiwan;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Malaysia;Australia;Denmark;Germany;Netherlands;New Zealand;China;Korea, Republic of